Increasing evidence in animal models and clinical trials for stroke, hypoxic encephalopathy for children, and traumatic brain injury have shown that mild hypothermia may attenuate ischemic damage and improve neurological outcome. However, it is less clear if mild intraoperative hypothermia during vascular neurosurgical procedures results in improved outcomes for patients. This review examines the scientific evidence behind hypothermia as a treatment and discusses factors that may be important for the use of this adjuvant technique, including cooling temperature, duration of hypothermia, and rate of rewarming.
I
n the 1950s, hypothermia at 25°C or less was used to protect the brain from ischemia during temporary occlusion of blood vessels during cerebral aneurysm surgery. 14, 43 However, this method fell out of favor due to lethal complications such as arrhythmia, 34 cardiac arrest, bleeding tendency, circulatory inhibition, and high infection rates leading to poor outcomes. 14, 42, 44 The publication of a study in 1987 showed a reduction of only 1-2°C significantly protected the brain against experimental stroke in rats. 8 Since then there have been many studies on the mechanisms by which mild (33-36°C) and moderate (28-32°C) hypothermia protects the brain from ischemic damage. Here we review the scientific evidence behind the use of hypothermia as a method of attenuating ischemic damage, and the available clinical evidence for the use of intraoperative hypothermia in vascular neurosurgical procedures. We also suggest future studies for this controversial clinical modality.
Scientific Evidence
A better understanding of the mechanisms of cell death following cerebral ischemia has been necessary to appreciate the way in which hypothermia may protect the brain. When cerebral blood flow is reduced, adeno sine triphosphate is depleted and anoxic depolarization and/or spreading depression such as depolarization follows. Glutamate is released from the intracellular to the extracellular space, stimulating N-methyl-d-aspartate receptors and leading to increased intracellular calcium levels. 10 Meanwhile, ischemia/reperfusion causes reactive oxygen species to be produced in large amounts. 9 These acute processes cause mitochondrial disruption, which coupled with BBB disruption, ultimately lead to necrotic neuronal death. 16 Furthermore, necrosis is exacerbated by free radicals generated from inflammatory factors such as matrix metalloproteinases, 52 nuclear transcription factor κB, 68 and stress-activated mitogen-activated protein kinase.
28 Apoptosis also occurs after stroke. After stroke, dying cells express proapoptotic proteins of the Bcl2 family, Bax, Bad, and Bid, 22 while surviving neurons upregulate antiapoptotic proteins of the Bcl-2 family, Bcl-2, and BclxL. Furthermore, caspase9 and 3 activity is stimulated when cytochrome c is released from the mitochondria into the cytosol, leading to apoptosis. Apoptosis and necrosis probably occur simultaneously and represent overlapping ends of a cell death continuum.
Thus, it is not surprising that a majority of research shows that blocking damaging cascades is an important mechanism underlying hypothermic protection. It has been shown that adenosine triphosphate depletion and anoxic depolarization are delayed or attenuated by intra Abbreviations used in this paper: BBB = blood-brain barrier; DHCA = deep hypothermic circulatory arrest; GOS = Glasgow Outcome Scale; IHAST = Intraoperative Hypothermia for Aneurysm Surgery Trial; SAH = subarachnoid hemorrhage; TBI = traumatic brain injury. ischemic hypothermia. 27, 60 It also maintains the integrity of the BBB, 16, 31 suppresses inflammation, 30,64 stops glutamate release, 7, 46 attenuates free radical production, 38 inhibits protein kinase C translocation, 55, 56 blocks matrix metalloproteinase expression, and inhibits necrosis and apoptosis. In addition, hypothermia attenuates astrocyte activity and inhibits white matter injury. 15, 32 Similarly, postischemic hypothermia prevents BBB permeability, 51 attenuates inflammation, 26 inhibits free radical generation, 25 and suppresses caspase activities. 63 In fact, almost every damaging cascade related to inflammation and BBB permeability seems to be inhibited by hypothermia.
Emerging research has also shown that mild and moderate hypothermia not only blocks cell signaling pathways of apoptosis and necrosis, but it also promotes the expression of antiapoptotic and prosurvival genes. Of note, the upregulation of the tumor suppressor gene p53 has also been shown to correlate with neuronal survival. Recent work has also shown that hypothermia selectively regulates certain signals in the PI3K/Akt kinase pathways that promote neuroprotection. 66, 67 Even as these reports have demonstrated the efficacy of hypothermia to protect the rodent brain, it is important to remember that mild and moderate hypothermia does not always lessen ischemic damage. Intra-ischemic hypothermia seems to promote the most neuroprotection for transient ischemia or reperfusion models, while neuroprotection for permanent ischemia models appears to be more variable. Furthermore, mild hypothermia protected the rodent brain only when applied immediately after reperfusion, whereas it failed to protect the brain when applied even after 15 minutes of reperfusion. 33 Therefore, it appears that the therapeutic time window, coupled with the duration and depth of hypothermia, is likely to be clinically relevant.
Translation Into Clinical Application
The overwhelming scientific evidence that mild to moderate hypothermia is an effective treatment in experimental models of stroke, neonatal hypoxia, and TBI has paved the way for clinical studies to evaluate the efficacy of this technique as a treatment. Though there is still some debate on the conclusions of studies, 6, 13, 20, 39, 54, 61 hypothermia has been implemented for the treatment of head trauma, stroke, and cardiac arrest. Another clinical modality for hypothermia is to use it intraoperatively to prolong the time of temporary occlusion during cerebral aneurysm procedures. Unfortunately little experimental and clinical evidence exist regarding the effectiveness of intraoperative hypothermia to attenuate ischemic damage during cerebral aneurysm procedures. In addition, the balance between oxygen supply and demand systemically and in the brain may worsen during aneurysm surgery. Despite the dearth of available evidence, a British survey showed that 58% of surgeons who replied (205 of 274) attempted to cool the patient during cerebral aneurysm surgery. 47 Here we review the clinical evidence and important considerations for the use of intraoperative hypothermia in vascular neurosurgical procedures and suggest future studies for this controversial clinical modality.
Cooling Temperature
In the 1950s and 1960s, Daw 14 and Michenfelder 43 and their colleagues reported the use of hypothermia at 25°C for cerebral aneurysm surgery. Neurosurgeons discontinued this method until experimental evidence in the laboratory showed that mild to moderate hypothermia could be beneficial in models of stroke and TBI while minimizing complications. 8, 11, 45 Cooling temperature is thus an important factor in considering clinical studies. Most of the clinical studies for intraoperative hypothermia have used between 33 and 35°C for hypothermic induction as detailed in Table 1 . 3, 12, 19, 24, 53, 61 Early studies first showed that mild intraoperative hypothermia is feasible.
3,12 Baker et al. 3 found that mild intraoperative hypothermia does not delay emergence of anesthesia compared with normothermia, although there was more shivering postoperatively in the mild hypothermia group. Hindman et al. 24 subsequently compared neurological outcomes of patients with and without acute stage of SAH undergoing aneurysm clipping under mild hypothermia (33.5°C) or normothermia (36.5°C) and found that there were no suggestions of excess morbidity or mortality. This study also found that among patients with SAH, there was a trend for patients in the hypothermia group to have a lower frequency of neurological deficit at 24 and 72 hours after surgery and more returning home than patients in the normothermia group. This association, however, was not significant because the study was underpowered. 24 However, the IHAST-a well-matched, modern, prospective, international, multicenter, randomized study of 1001 patients in good grades who had aneurysmal SAH-showed that there was no difference in outcome as assessed using the GOS between the mild intraoperative hypothermic and normothermic groups. 61 Furthermore, there was a trend toward more bacteremia in the hypothermic group, although there was no difference in meningitis, pneumonia, urinary tract infection, or wound infection rate.
Mild hypothermia is usually used in the context of temporary clipping at the proximal and/or distal parent arteries. Total local circulatory arrest is not always safe or even possible in eloquent anatomical conditions and in large or giant aneurysms. Giant intracranial aneurysms 1, 37 or complex cerebrovascular lesions 21 may necessitate the use of DHCA (15-18°C). Unfortunately there are significant complications associated with this procedure that include postoperative intracranial hematoma, some type of cerebral infarction, cranial nerve morbidity, fatal myocardial infarction, and sepsis. 36 Despite the significant complications, the use of DHCA has significantly improved the prognosis in patients with large or giant cerebral aneurysms, 17, 62 especially with the advent of the closedchest approach. 4, 57, 58, 65 A recent study with well-selected patients using the most up-to-date anesthetic procedures showed that there was 1 complication related to cardiopulmonary bypass in a group of 12 patients. 37 Although this method is feasible, carefully weighing the risk/benefit ratio is important due to the significantly higher risk of morbidity and mortality.
Cooling Time
Experimental studies have shown that mild hypothermia protected the rodent brain only when applied immediately after reperfusion, whereas it failed to protect the brain when applied even after 15 minutes of reperfusion. 33 Reaching the target temperature at the time of temporary occlusion during vascular neurosurgery may thus be crucial to improved neurological outcome. In addition, a clinical study showed that there was improved neurological outcome for patients with TBI when hypothermia was applied for 24 hours after injury. 39 It is therefore likely that the timing of hypothermic application after surgery may be important for vascular neurosurgical procedures. Unfortunately, most of the clinical studies did not report the target hypothermic temperature at the time of clipping or the duration of hypothermia, so it may be difficult to evaluate their conclusions. In the IHAST it was reported that the target temperature was reached before or at the time of clipping. 61 The cooling time in the IHAST was also limited to the mean operative time of 5-6 hours only, so it is possible that their results could be explained by insufficient cooling time to adequately attenuate ischemic damage.
Rate of Rewarming
Animals studies on TBI have demonstrated that rapid rewarming can result in poorer outcomes due to enhanced inflammatory response, 23 decreased axonal microtubules, 40 and increased cerebral metabolic rate. 18 Likewise, clinical studies on the use of hypothermia for TBI have shown that rapid rewarming in patients with TBI resulted in poorer outcomes compared with slow rewarming 41, 50 due to increased risk of hyperkalemia and imbalances in cerebral blood flow. 29, 35 Unfortunately, most clinical studies on mild intraoperative hypothermia and DHCA did not record the rate of rerewarming, 12, 19, 21, 24, 37, 53 and rapid rewarming after surgery is commonly practiced. 48 Investigators in the IHAST trial rapidly rewarmed their patients after surgery, 61 which could partially explain their results.
Method of Cooling and Rewarming
Since the cooling temperature, depth and duration of hypothermia, and rate of rewarming may be important to maximize benefit of mild intraoperative hypothermia, the method of cooling and rewarming must be considered. The current methods to control body temperature intraoperatively include surface cooling/rewarming with water blankets and convection devices, 12, 19, 21, 24, 37, 53 DHCA, and a new InnerCool catheter (Cardium Therapeutics) method. 59 It has been reported that the surface cooling method, especially if combined with rapid infusion of cold intravenous fluids, 5,49 can achieve a rapid systemic and brain temperature decrease with stable control. However, it is usually difficult to control the rewarming rate with this technique. 3 Baker et al. 3 found that it was difficult to control rewarming with water blankets and convection devices; after surgery patients in the hypothermic group had a body temperature of 35.8 ± 1.0°C and patients in the normothermic group had a body temperature of 37.1 ± 0.5°C. In our previously published multicenter study, we found that cooling rates in endovascular and surface blanket groups averaged 4.77 and 0.87°C/hour, respectively (p < 0.001). Most importantly at the time of temporary arterial or aneurysm clip placement, 99% of the endovascular group and 20% of the surface blanket group had reached the target of 33°C (p < 0.001). Also the rewarming rates were significantly faster for the endovascular technique (1.88 vs 0.69°C/hour, p < 0.001) leading to near normothermia in > 80% of cases at the end of the procedure. There had been no clinically significant catheterrelated thrombotic, bleeding, or infectious complications in the endovascular group. We now use the endovascular cooling method with the InnerCool catheter in all cerebrovascular procedures with potential temporary vessel occlusion (Fig. 1) . To initiate cooling with the InnerCool system, the catheter is inserted in the operating room after induction of general anesthesia via a standard introducer sheath into the femoral vein. The catheter is advanced to the inferior vena cava until the distal tip of the catheter is just below the right atrium. Correct catheter placement is confirmed using portable fluoroscopy. The desired target temperature is set with the console control panel, and the cooling mode is activated. The rate of cooling is 5.0 ± 0.5°C/hour.
As soon as the hypothermic target temperature of 34°C is reached, the Celsius Control system automatically begins to turn off and on intermittently as needed to maintain the patient at target temperature. To initiate active rewarming near the end of surgery, the target temperature is reset to normothermia via the console control panel. To initiate rewarming at a rate of 2.2 ± 0.2°C, the Celsius Control system circulates warm saline through the catheter to rewarm the blood as it circulated near the catheter. The catheter is removed at the end of surgery. As soon as the femoral sheath is removed, direct pressure is applied to the femoral access site until hemostasis is achieved.
The IHAST
The IHAST is the most thorough clinical evaluation of mild intraoperative hypothermia as a method to attenuate ischemic damage during vascular neurosurgical procedures. This study showed that there was no significant difference in neurological outcome between the mild hypothermic and normothermic group, 61 and a long-term follow-up in a smaller subgroup (163 patients) also noted no significant differences between mild intraoperative hypothermic and normothermic group at 9 or 15 months. 2 However, it is possible that the results could be explained by insufficient cooling time and rapid rewarming. The assumption was that enrollment of 1000 patients would permit detection of a 10% absolute and 15% relative improvement in the fraction of patients with a good outcome, as defined by a score of 1 on the GOS. The study, however, only reached a 3.2% absolute and 5.0% relative increase in the fraction of patients in the hypothermia group with GOS scores of 1. Although the study design, sample size, adjudicated outcomes, compliance, and nearperfect followup make these results seem robust, even with 1001 good-grade patients the study appears underpowered. A possible explanation is that this study was performed in patients at low risk for ischemic injury, whereas highrisk patients would be more likely to benefit from mild intraoperative hypothermia. In addition, the GOS is a relatively crude measurement of cognitive function and may not detect subtle changes. Finally, subgroup analysis of the data showed that male patients and patients undergoing surgery 8-14 days after SAH had improved neurological outcomes, so it is possible that some patients at low risk for ischemic damage may benefit slightly from mild intraoperative hypothermia.
Future Studies
Although it is safe to use mild intraoperative hypothermia during vascular neurosurgical procedures, it remains controversial whether this method results in improved neurological outcome. Even though the multicenter trial failed to reach the targeted end point, the data were suggestive of a clinical benefit with hypothermia. Endovascular cooling appears to be a superior technique with minimum temperature fluctuations and faster cooling and rewarming times, when compared with the current method of using water blankets and convection devices.
59
In future studies a more stringent selection of highrisk patients and more precise imaging and clinical outcome measures will be needed. Possible intraoperative measurements (for instance, using microdialysis to monitor metabolite changes during hypothermia) will further help to understand the clinical relevance of this technique.
Conclusions
There is ample evidence from preclinical studies that hypothermia leads to blockage of damaging cascades and is protective against brain ischemic injury. In the experimental and clinical settings it appears that the therapeutic time window, coupled with the duration and depth of hypothermia are likely to be key factors determining the success of this method. The literature demonstrates that although it is apparently safe to use mild intraoperative hypothermia during vascular neurosurgical procedures, it remains a controversial method until further studies are performed.
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